Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study

Lancet

Volumn 357, Issue 9260, 2001, Pages 905-910

  Steiner, G ^a,b   Hamsten, A ^a,b,d   Hosking, J ^a,j   Stewart, D ^a,j   McLaughlin, P ^a,i,n   Gladstone, P ^a,d,i,n   Sole, M ^a,l   Syvanne, M ^a,d,n   Camelon, K ^b,d   Schloegl, G ^b   Genest, J ^c   Reeves, F ^c,n   Savard, R ^c   Letarte, A ^c   Bellavance, N ^c   Touchette, J ^c   Latour, Y ^c   Marchand, P ^c   Rondeau, C ^c   Rivard Gervais, N ^c   Belanger, A ^d   Hamel, D ^d   Dumas, R ^d   Sandri, M ^d   Morin, N ^d   Caponi, E ^d   Barbeau, C ^d   Gauthier, S ^d   Ooi, T C ^d   Davies, R F ^d   Braaten, J T ^d   Baker, A ^d   Favreau, C ^d   Collar, C ^d   Zinman, B ^d   Aldridge, H ^d   Donat, D J ^d   Tsui, E ^d   Barnie, A ^d   DiMonte, L ^d   MacLean, S ^d   Bond, M ^d,i,o   Martin, C ^d   Zawacki, R ^d   Dziuran, K ^d   M R Gouveia, ^d   Taskinen, M R ^d   Nieminen, M ^d   Nikkila, K ^d   Virtanen, K ^d   Makimattila, S ^d   Malmstrom, R ^d   Kohtamaki, H ^d   Jamsen P ^d   Salo, A ^d   Puupponen, M ^d   Kesaniemi A ^d   Ikaheimo M ^d   Ukkola, O ^d   Salmela, P ^d   Savolainen, M ^d   Huikuri, H ^d   Airaksinen, J ^d   Koistinen, J ^d   Mannermaa, L ^d   Ukkola, L ^d   Ketonen, K ^d   Silaste, M L ^d   Salovaara, A ^d   Efendic, S ^d   Svane, B ^d   Hellekant, C ^d   Bavenholm, P ^d   Karlen, A ^d   Hadell, K ^d   Franson, K ^d   Mohlkert, D ^d   Nordlander, R ^d,n   Ehrenstig, L ^d   Tan, M H ^d   Title, L M ^d   Johnstone, D ^d   Winch, S ^d   Higgins Bowser, I ^d   Shlossberg, A ^d   Murdock, H ^d   Elliott, T ^d   Fung, A ^d   Jalbert, A ^d   Leung, S ^d   Turnbull, S ^d   Norman, E ^d   Farez, C ^d   Tavolaro, O ^d   Sachs, R N ^d   Sedjari, F ^d   Laakso, M ^d   Kettunen, R ^d   Eranen, J ^d   Lehto, S ^d   Raisanen, R ^d   Jantunen, A ^d   Valve, R ^d   Toivanen, A ^d   Frohlich, J ^e   Vannetta, H ^e   Bowden, F ^e   W Seccombe, D ^f,h   Ehnholm, C ^g   Gref, C G ^g   Ikonen, M ^g   Sundvall, J ^g   McGuinness, C ^h   Ho, A ^h   Hamilton, J ^h   Pritchard , H ^h   Allard, N ⁱ   Bui, S ⁱ   Van Der Wal, H ⁱ   Davis, C E ^j   Tyroler, H A ^j   Curtis, R C ^j   Miles , M ^j   Khaltaev , N ^k   Kirkeeide, R ^l   Frick, H ^l   Hata, Y ^l   Rifkind, B ^l   Zimmet , P ^l   Gent, M ^m   Schonfeld, G ^m   de Bono , D ^m   Carter , A ⁿ   Ansquer, J C ^o   Fraitag, B ^o   Guivarc'h, P H ^o   Irvine, A ^o   Jacovella, J ^o   Munoz, A ^o   Rode, H ^o   Yacine, A ^o   Asmar Kristiansen, D ^o   Bonnefous , F ^o   Belanger, F ^o   Brown, M ^o   DeLorme, L ^o   Galos, C ^o   Jenkins, R ^o   Lanoue, C ^o   Moussalli, R ^o   Murtomaki, E ^o   Zandomenighi, F ^o   more..

^a Writing Committee

^b TORONTO GENERAL HOSPITAL   (Canada)

^c Montreal Chest Clinic   (Canada)

^d St Paul's Hospital ^*  (France)

^e ST PAUL S HOSPITAL   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h Canadian Reference Laboratory   (Canada)

ⁱ Statistical Coordinating Centre ^*  (Canada)

^j Statistical Coordinating Centre   (United States)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

^l Safety and Data Monitoring Committee ^*

^m Safety and Data Monitoring Committee

ⁿ Cardiac Endpoint Committee

^o Laboratories Fournier

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035941990     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04209-4     Document Type: Article

References (30)

1. Steiner G. Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol 1985; 189: 277–97.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
3. Abbott RD, Donahue RP, Kannel WB, Wilson PWF. The impact of diabetes on survival following myocardial infarction in men vs women. JAMA 1988; 260: 3456–60.
4. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993; 22: 1788–94.
5. Lehto S, Pyorala K, Miettinen H, et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med 1994; 236: 291–97.
6. Mykkanen L, Laakso M, Pyorala K. Asymptomatic hyperglycemia and atherosclerotic vascular disease in the elderly. Diabetes Care 1992; 15: 1020–30.
7. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Rev 1998; 19: 583–92.
8. Fuller JH, McCartney P, Jarrett RJ, et al. Hyperglycemia and coronary heart disease: the Whitehall Study. J Chron Dis 1979; 32: 721–28.
9. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus: the Finnish studies. Ann Intern Med 1996; 124: 127–30.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
11. Vokonas PS, Kannel WB. Diabetes mellitus and coronary heart disease in the elderly. Clin Geriatr Med 1996; 12: 69–78.
12. Stamler R, Stamler J. Asymptomatic hyperglycemia and coronary heart disease: a series of papers by the International Collaborative Group, based on studies in fifteen populations. J Chron Dis 1979; 32: 683–837.
13. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.
14. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421–30.
15. UK Prospective Diabetes Study Group. UKPDS 27: plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683–87.
16. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologia 1996; 39: 1655–61.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
18. McGuinness C, Seccombe DW, Frohlich JJ, et al. Laboratory standardization of a large international clinical trial: the DAIS experience. Clin Biochem 2000; 33: 15–24.
19. McLaughlin PR, Gladstone P. Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Catheterization Cardiovasc Diagn 1998; 44: 249–56.
20. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–98.
21. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992; 339; 563–69.
22. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–18.
23. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614–21.
24. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98: 2513–19.
25. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57.
26. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820–25.
27. Pajunen P, Nieminen MS, Taskinen MR, Syvanne M. Quantitative comparison of angiographic characteristics of coronary artery disease in patients with noninsulin-dependent diabetes mellitus compared with matched nondiabetic control subjects. Am J Cardiol 1997; 80: 550–56.
28. Archbold RA, Timmis AD. Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies. Curr Opin Lipidol 1999; 10: 527–34.
29. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 344: 1383–89.
30. Waters D. Lessons from coronary atherosclerosis “regression” trials. Cardiol Clin 1996; 14: 31–50.